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Abstract
In December 2019, the world started to face a new pandemic situation, the severe
acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). Although coronavirus
disease (COVID‐19) clinical manifestations are mainly respiratory, major cardiac
complications are being reported. Cardiac manifestations etiology seems to be
multifactorial, comprising direct viral myocardial damage, hypoxia, hypotension,
enhanced inflammatory status, ACE2‐receptors downregulation, drug toxicity, en-
dogenous catecholamine adrenergic status, among others. Studies evaluating pa-
tients with COVID‐19 presenting cardiac injury markers show that it is associated
with poorer outcomes, and arrhythmic events are not uncommon. Besides, drugs
currently used to treat the COVID‐19 are known to prolong the QT interval and can
have a proarrhythmic propensity. This review focus on COVID‐19 cardiac and ar-
rhythmic manifestations and, in parallel, makes an appraisal of other virus epidemics
as SARS‐CoV, Middle East respiratory syndrome coronavirus, and H1N1 influenza.
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1 | INTRODUCTION
Since the last December, the entire world is facing a new pandemic
situation, the severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2). After emerging from Wuhan‐China, the coronavirus
disease‐2019 (COVID‐19) quickly spread throughout the world. Due
to all its unknown factors, physicians are passing through real‐time
learning process. As the disease spreads, a massive wave of in-
formation takes over scientific journals and media.
This new virus belongs to the same severe acute respiratory
syndrome‐coronavirus (SARS‐CoV) and Middle East respiratory
syndrome‐coronavirus (MERS‐CoV) family. Although COVID‐19
clinical manifestations are mainly respiratory, with the growing
number of infected patients, major cardiac complications have been
reported in a considerable number of patients with COVID‐19.1‐3
SARS‐CoV‐2 infection is associated with a variety of pro‐
inflammatory mediators that may play important roles in the pa-
thophysiology of cardiac and arrhythmic complications. In a single
center study1 cardiac injury was observed in 19% of hospitalized
patients with COVID‐19, and it was associated with higher risk of in‐
hospital mortality. Therefore, it is plausible that these patients have
an even higher risk of cardiac arrhythmias.
Abbreviations: ATP, antitachycardia pacing; CHF, congestive heart failure; CO, cardiac output; COVID‐19, coronavirus disease‐2019; CRT‐D, cardiac resynchronization therapy defibrillator;
HCQ, hydroxychloroquine; HF, heart failure; HR, hazard ratio; hs‐cTnI, high‐sensitivity cardiac troponin I; ICD, implantable cardiac defibrillator; ICU, intensive care unit; LVEF, left ventricular
ejection fraction; MERS‐CoV, Middle East respiratory syndrome coronavirus; NHC, National Health Commission of China; OR, odds ratio; RBBB, right bundle branch block; SARS, severe acute
respiratory syndrome; SARS‐CoV, severe acute respiratory syndrome‐coronavirus; SARS‐CoV‐2, severe acute respiratory syndrome‐coronavirus 2; SCD, sudden cardiac death;
SVT, supraventricular tachycardia; TnT, troponin T; VA, ventricular arrhythmias; VF, ventricular fibrillation; VT, ventricular tachycardia.
Aiming to shed some light in this issue, we performed this review
focused on COVID‐19 cardiac manifestations not only by analyzing
the preliminary available evidence about the virus, but also by
making comparative considerations with SARS‐CoV, MERS‐CoV, and
H1N1 influenza.
1.1 | Lesson from previous epidemics
Much of our present knowledge of SARS‐CoV‐2 comes from previous
historical epidemics that preceded the current outbreak, as SARS‐
CoV, MERS‐CoV, and H1N1 influenza syndromes. It was observed,
during these outbreaks, a significant association between underlying
cardiovascular disease, myocardial injury, and worse outcomes.4
The first human infection by a new strain of coronavirus, the
SARS‐CoV, was reported in 2002. At that time it was known that, at
least in rabbits, coronavirus infections could induce cardiomyopathy
resulting in cardiac chambers dilatation and systolic function im-
pairment, simulating other dilated cardiomyopathies.5
In humans, hypotension, cardiac arrhythmias, and even sudden
cardiac death (SCD) were described as possible SARS‐CoV manifes-
tations.6 In a cohort of 121 patients, Yu et al demonstrated that sinus
tachycardia was the commonest cardiovascular SARS‐CoV finding
with an overall incidence of 72%. Persistent tachycardia mean
duration was 12.7 days with a mean heart rate of 117 beats/min
(range: 102‐150 beats/min) and the tachycardia remained persistent
in nearly 40% of patients within 30 days after hospital discharge. The
incidence of tachycardia during the third hospitalization week, when
most patients were afebrile, could be related to drug treatment, such
corticosteroid and ribavirin. However, corticosteroid therapy was not
associated with persistent tachycardia during follow‐up. Hence,
longstanding tachycardia could eventually be due to autonomic tone
changing. Or, alternatively, sinus tachycardia secondary to cardio-
pulmonary or peripheral deconditioning since this disease resulted in
prolonged bed rest.7
Besides these findings, significant sinus bradycardia was seen in
18 (14.9%) patients. Unlike tachycardia, which was persistent,
bradycardia was somewhat transient with a mean heart rate of
43 beats/min (range: 38‐49 beats/min) and a mean duration of
2.6 days. Reversible cardiomegaly was also reported in 13 (10.7%),
with no clinical evidence of heart failure (HF). Transient atrial
fibrillation was observed in one patient.7
Lau et al additionally described that palpitation, in the form of
tachycardia at rest or mild exertion, was noted amongst patients
recovering from SARS. Possible causes, according to them, were
deconditioning, impaired pulmonary function, impaired cardiac
function, cardiac arrhythmia, thyroid dysfunction, anemia, autonomic
dysfunction, and anxiety state.8
Trying to explain the occurrence of cardiac arrest in 15 patients
with SARS, Pan et al suggested some possible mechanisms: (a) lung
injury caused by SARS virus leading to hypoxemia and an unsteady
state in myocardial electricity; (b) SARS direct causing new myo-
cardial cells and/or conduction system damage; (c) SARS infection
aggravating pre‐existing myocardial conditions, or conduction dis-
turbances; and (d) extreme anxiety leading to further endogenous
catecholamine release, causing myocardial electrical instability (see
Figure 1).9
In the setting of the 2012 MERS‐CoV syndrome, despite some
similarities with SARS‐CoV, the early mortality rate for the former
achieved 60%,10 remaining higher than 35% during the overall out-
break period, while for SARS‐CoV the mortality rate was about
10%.11 A meta‐analysis suggested that MERS‐CoV infection was
more likely to occur in patients with underlying cardiovascular dis-
eases.12 In terms of overall complications, renal failure (40.9%),
F IGURE 1 Mechanisms and consequences of COVID‐19 myocardial damage. COVID‐19, coronavirus disease
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cardiac arrhythmias (15.7%), hepatic dysfunction (31.4%),13 besides
pericarditis, and hypotension were the most commonly reported.14 In
a case report published by Alhogbani, he describes an acute
myocarditis caused by MERS‐CoV; a 60‐year‐old presenting with
respiratory symptoms, chest pain, and persistent tachycardia
(120 bpm). Echocardiogram demonstrated severe left ven-
tricular function impairment, cardiac magnetic resonance showed
typical findings of acute myocarditis, and sputum was positive for
MERS‐CoV. The patient was intubated and required hemodialysis.
After 6 weeks of intensive care unit (ICU) and 1 month of ward
hospitalization, he was discharged in stable condition.15
Last but not least, influenza virus infection is well‐known to ag-
gravate plenty of cardiovascular disorders, being associated with
myocarditis, myocardial infarction, and HF exacerbation.16
An interesting survey conducted by Madjid et al tested the
possible effect of seasonal influenza on the occurrence of ven-
tricular arrhythmias (VA) requiring shock or antitachycardia
pacing (ATP) treatment in patients with implantable cardiac defi-
brillator or cardiac resynchronization therapy defibrillator. The
results indicated that more shocks were delivered during influenza
season than during other periods of the year, suggesting a corre-
lation between higher arrhythmia burden and influenza season.
The multivariate generalized linear model showed that during high
influenza activity, patients were more likely to have a VA treated
with shock (odds ratio [OR]: 1.06; P < .001) or ATP (OR: 1.06;
P < .0001).17
Multiple mechanisms have been proposed to explain influenza
triggering arrhythmias, among them severe systemic, arterial, and
myocardial inflammatory reaction seems to be one of the most
plausible. Moreover, influenza is known to exacerbate congestive
heart failure (CHF) and increase CHF‐related hospital admissions.18
Decompensated CHF, besides leading to hospitalization, is related to
electrical myocardial homeostasis impairment, causing ventricular
tachycardias (VTs) treated with shock or ATP therapy. In patients
with underlying ischemic cardiomyopathy, the worsening of ischemia
by increased oxygen demand and potential acute coronary syn-
dromes led by influenza can also have a role in the increase of
arrhythmic events.17
These concepts were strengthened by a nationwide Denmark
studied, which showed a strong relationship between yearly influenza
vaccination and mortality in patients with HF. In this study, annual
influenza vaccination was associated with 18% reduction in the ad-
justed risk of all‐cause death and 18% reduction in the adjusted risk
of cardiovascular death (P < .001, for both). Remarkably, those who
received more than one seasonal vaccination also had a more pro-
nounced reduction in atrial fibrillation incidence (hazard ratio [HR]:
0.94; P = .009). According to this study, influenza infection may result
in increased metabolic demand, hypoxia, and adrenergic surges,
which may lead to acute decompensation or exacerbation of HF.
Additionally, the infection may induce a hypercoagulable state and
trigger acute coronary syndromes, resulting in further left ventricular
function deterioration, or it could cause direct myocardial depres-
sion. Based on these results, the authors advocated that influenza
vaccination may be a valuable treatment strategy to improve survival
in patients with HF.19
1.2 | Coronavirus disease
Despite not being particularly lethal, SARS‐CoV‐2 is very con-
tagious. In a published clinical cohort of patients with COVID‐19,
they observed that acute cardiac injury, shock, and arrhythmias
were present in 7.2%, 8.7%, and 16.7% of patients, respectively,
with higher prevalence amongst patients requiring intensive care.2
In this report, myocardial injury biomarkers levels were significantly
higher in patients requiring ICU admission than in those not treated
in the ICU (median creatine kinase‐MB level 18 U/l vs 14 U/l;
P < .001; and high‐sensitivity cardiac troponin I [hs‐cTnI] level
11.0 pg/mL vs 5.1 pg/mL; P = .004), suggesting that patients with
severe symptoms often have complications involving acute myo-
cardial injury.2 Overall, arrhythmia rate was also more frequent in
ICU patients (44.4% vs 6.9%; P < .001). Despite the relevance of
these initial data, the authors did not provide any arrhythmia
classification or definition Table 1.
A study from Shi et al evaluated a single‐center cohort of
416 patients hospitalized due to COVID‐19. He observed that car-
diac lesion, defined by hs‐cTnI >99th percentile of on admission, was
present in 19.7%, with median value of 0.19 (0.08‐1.12) μg/L in this
group. Compared with those without cardiac injury, patients with
cardiac injury required more noninvasive ventilation (46.3% vs 3.9%;
P < .001) and invasive mechanical ventilation (22.0% vs 4.2%;
P < .001), and also had a higher mortality (51.2% vs 4.5%; P < .001). It
is remarkable that the elevated troponin group was older and sig-
nificantly more ill, but after adjustment for all the possible con-
founding factors, still the cardiac injury was a predictor of mortality
(HR: 4.26; 95% CI: 1.92‐9.49).1
In another small report, Huang et al demonstrated that SARS‐
CoV‐2 associated myocardial injury occurred on 5 out of 41 patients,
and was manifested as an increase in hs‐cTnI levels (>28 pg/mL).
Among these five patients, ICU management was required in four,
indicating the severe nature of the myocardial injury in patients with
COVID‐19.20
In a study by Guo et al, 187 patients with SARS‐CoV‐2 positive
were analyzed, stratified by the level of troponin, which was elevated
in 27.8%. During hospitalization, patients with elevated troponin T
(TnT) levels developed more frequently complications as acute re-
spiratory distress syndrome (57.7% vs 11.9%), malignant VAs (11.5%
vs 5.2%), acute coagulopathy (65.8% vs 20.0%), and acute kidney
injury (36.8% vs 4.7%), compared with those with normal TnT levels.
But the most impressive observation is that mortality was markedly
higher in patients with elevated plasma TnT levels than in patients
with normal TnT levels (59.6% vs 8.9%).21
Contrary to the above mentioned studies Zhou et al comparing
survivors and non‐survivors in a cohort of 191 patients from
two hospitals in Wuhan, found that, despite more frequent in
non‐survivors (46% vs 1%; P < .001), hs‐cTnI >28 pg/mL was not
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associated with mortality in multivariate analysis. Even though, it is
remarkable that this study was unpowered to draw conclusions from
this analysis due to the excess of variable for only 54 events.22
Acute myocarditis, as well as VAs might represent the first
clinical manifestation of SARS‐CoV‐2 infection.3,44 In the epicenter of
the current Italian epidemic, SCD likely occurred in many non-
hospitalized patients with mild symptoms who were found dead
home while in quarantine. Myocardial biomarkers should be eval-
uated in all patients with COVID‐19 for risk stratification and prompt
intervention. Even after hospital discharge, we should consider that
myocardial injury might result in atrial or ventricular fibrosis, the
substrate for subsequent cardiac arrhythmias. The extent of myo-
cardial scar, as assessed with cardiac magnetic resonance, might be a
powerful tool to better stratify the arrhythmic risk in patients
recovered from COVID‐19 who had evidence of myocardial injury at
the time of infection.
Another relevant aspect of COVID‐19 infection is that early di-
agnosis can be confounded in patients with chronic cardiac condi-
tions, once the most frequent symptoms, like fatigue (51%, 95%
CI: 34%‐68%), dyspnea (30%, 95% CI: 21%‐40%), and cough (67%,
95% CI: 59%‐76%)25 can also be manifestations of decompensated
HF or arrhythmic syndrome. Corroborating this concern, the Na-
tional Health Commission of China (NHC) reported that among
SARS‐CoV‐2 infection confirmed cases, cardiovascular symptoms
were the first presentation in some patients. The problem behind
these atypical presentations is that patients suffering from heart
palpitations and chest tightness rather than respiratory symptoms,
such as fever and cough, had a delayed COVID‐19 diagnosis.26 Still
TABLE 1 Cohorts that evaluated cardiac manifestations in SARS‐CoV, MERS‐CoV, H1N1, and SARS‐CoV‐2
First author, y Number of patients Cardiac manifestations Troponin
In‐hospital
mortality
SARS‐CoV Lee et al39 138 Acute HF (1 pt) None 3.6%
Booth et al40 144 Pulse >100 bpm (46%) ND 6.5%
Chest pain (10.4%)
Li et al23 46 RBBB 15.2% ND 13%
LVEF‐HF 1 pt (EF 30.2%)
Initial TTE compare with 30 d control:
Lower LVEF
Lower doppler‐derived CO
Yu et al7 121 Tachycardia (71.9%) ND ND
Hypotension (50.4%)
Bradycardia (14.9%)
Rev cardiomegaly (10.7%)
MERS‐CoV Saad et al13 70 Arrhythmias (15.7%) ND 60%
Al‐Tawfiq et al41 17 X‐ray cardiomegaly (53%) ND 76%
Chest pain (7%)
Assiri et al43 47 Chest pain (15%) ND 60%
Al‐Albdallat et al14 9 Chest pain (44%) ND 22%
Pericarditis (1 pt)
VT (1 pt)
SVT (1 pt)
H1N1 Influenza Schoen et al42 160 Chest pain (5%) ND Zero
SARS‐CoV‐2 Huang et al20 41 Shock (7%) Elevated in 12.2% 15%
Wang et al2 118 Arrhythmia (16.7%) Mean 6.4 pg/mL 4.3%
Shock (8.7%)
Acute cardiac injury (7.2%)
Shi et al1 416 Chest pain (3.4%) Elevated in 19.7% 13.7%
ST‐depression on ECG (0.7%)
Zhou et al22 191 HF (23%) Elevated in 17% 28.2%
Hypotension (1%)
HR > 125 bpm (1%)
Guo et al21 187 VT/VF (5.9%) Elevated in 27.8% 23%
Abbreviations: CO, cardiac output; ECG, electrocardiogram; EF, ejection fraction; HF, heart failure; HR, heart rate; MERS‐CoV, Middle East respiratory
syndrome coronavirus; ND, not disclosed; pt, patient; LVEF, left ventricular ejection fraction; TTE, transthoracic echocardiogram; RBBB, right bundle
branch block; Rev, reversible; SARS‐CoV, severe acute respiratory syndrome‐coronavirus; SVT, supra ventricular tachycardia; VF, ventricular fibrillation;
VT, ventricular tachycardia.
1006 | KOCHI ET AL.
according to the NHC, among the people who died from COVID‐19,
11.8% had substantial heart damage, with elevated troponin I levels
or cardiac arrest during hospitalization.26
Explanatory theories regarding COVID‐19 cardiovascular affec-
tion postulate that chronic cardiovascular diseases may become un-
stable in the setting of a viral infection as a consequence of the
imbalance between the infection‐induced increase in metabolic
demand and reduced cardiac reserve.2 This imbalance, concurrent
with an accentuated inflammatory response and myocardial
damage, could raise the risk of acute coronary syndromes, HF, and
arrhythmias.
The deleterious SARS‐CoV‐2 infection myocardial effects could
also be perpetuated by the prompt and severe downregulation of
myocardial and pulmonary ACE2 pathways, thereby mediating
myocardial inflammation, lung edema, and acute respiratory failure.27
ACE2 is widely expressed not only in the lungs but also in the car-
diovascular system and, therefore, ACE2‐related signaling pathways
might even have a role in heart injury. Other proposed mechanisms
of myocardial injury include a cytokine storm triggered by an im-
balanced response by type 1 and 2 T‐helper cells,20,28 strong
interferon‐mediated immunopathological events,29 and respiratory
dysfunction and hypoxemia caused by COVID‐19, resulting in da-
mage to myocardial cells. Therapeutic use of corticosteroids, in this
context, would further augment the possibility of adverse cardio-
vascular events.
Regarding hypoxemia caused by COVID‐19, it is relevant to
highlight that this condition can trigger atrial fibrillation, which is the
most common arrhythmia among elderly individuals, and that atrial
fibrillation can become persistent even before pulmonary improve-
ment. Furthermore, the systemic inflammatory response would make
anticoagulation therapy for atrial fibrillation very complex.30
1.3 | Chloroquine and hydroxychloroquine side
effects on cardiovascular system
Another essential aspect to be discussed is about chloroquine car-
diovascular side effects since this is one of the promising drugs that
have been tested in patients with COVID‐19. It is well‐reported that
long‐term chloroquine use may increase depolarization length dura-
tion and Purkinje fiber refractory period,31‐34 ultimately leading to
atrioventricular nodal and/or His system malfunction.31
As an antimalarial drug, both chloroquine and hydroxy-
chloroquine (HCQ) are accumulated in lysosomes, directly inhibiting
phospholipase activity, inducing cytoplasmic inclusion body forma-
tion, increasing lysosomal pH, and causing protein inactivity.31,35 Due
to these properties, drug‐induced atrial and VAs have been asso-
ciated with their use.31‐35 The most usual electrocardiographic al-
teration is fascicular block, which can lead to advanced types of
atrioventricular block, generally associated with syncope.36
HCQ can also induce QT interval prolongation, an extremely rare
but potential fatal side effect, due to the risk of induced polymorphic
VT and SCD. The proposed mechanism by which HCQ causes QT
interval prolongation is not well understood. In 2015, Capel et al
demonstrated, in guinea pig sinoatrial node myocytes, an inhibitory
effect of the HCQ on the hyperpolarization‐activated current ion
channels (also known as “funny current” channels), along with de-
layed rectifier potassium currents, and L‐type calcium ion currents.37
Inhibitory effects on pacemaker cells were shown to cause delayed
rates in depolarization leading to decreased heart rates. These
findings may correlate with a proposed mechanism by which re-
fractory action potentials in cardiac myocytes may lead to pro-
longation of QT interval due to delayed depolarization and
repolarization from abnormal ion currents.38 QT prolongation in
individual medical therapy is not always predictable, dose adjust-
ments and/or additional monitoring with electrocardiograms may be
appropriate in some cases. HCQ proarrhythmic risk must be mon-
itored in patients with underlying cardiovascular or renal disorders,
and high caution should be posed in the case of electrolyte im-
balance, dysrhythmias or concurrent use of QTc‐prolonging drugs.38
2 | CONCLUSION
Acute lung injury is a common problem in patients with COVID‐19
and results in significant morbidity and mortality. However, in-
creasing clinical and epidemiological evidence suggests that
COVID‐19 infection is associated with myocardial injury and
arrhythmic complications.
Even though the prevalence of COVID‐19 arrhythmogenic ef-
fects has yet not been reported, close cardiovascular surveillance is
advisable, particularly in patients with more severe presentation and
in those with increased baseline risk due to previous cardiac co-
morbidities. Since many medications are being used empirically to
treat the infection and/or symptoms, there is a need to increase
awareness to possible drug interactions and close monitoring in at-
rioventricular conduction and QT interval.
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